Leadership

Home  >  About  >  Leadership

Executive Team

Portrait

Santiago Arroyo,, M.D., Ph.D., Senior Vice President, Development and Chief Medical Officer

See bio

Dr. Arroyo joined Momenta in June of 2017. He is responsible for preclinical and clinical development and regulatory affairs. He joins Momenta from Boston Pharmaceuticals, where he was Chief Medical Officer. Previously he was Senior Vice President, Head of Clinical Research and Chief Medical Officer of Biotherapeutics and Pharmatherapeutics at Pfizer Inc. in the areas of Cardiovascular and Metabolism, Pain, Neuroscience, Regenerative Medicine and Rare Diseases. He was previously Therapeutic Area Head for Neurosciences, Discovery Medicine and Clinical Pharmacology at Bristol-Myers Squibb and Neurology Global Therapeutic Area Head for Eisai Global Clinical Development. Dr. Arroyo was an Instructor in Neurology at the Johns Hopkins Hospital and Associate Professor of Neurology and Director of the Epilepsy Program at the Medical College of Wisconsin and at the Hospital Clinic of Barcelona, Spain. Dr. Arroyo received his medical degree from the Autonomous University of Madrid and his Ph.D. from the University of Barcelona, Spain.

Portrait

Jo-Ann Beltramello, Chief Human Resources and Infrastructure Officer

See bio

Ms. Beltramello joined Momenta in October of 2007. Ms. Beltramello is responsible for all human resources, IT, and facilities matters for the company. She was previously the Chief Human Resources Officer at Multiplan, a provider of health care cost management solutions with over 2,000 employees conducting business in all fifty states. In this role, she was responsible for all human resource operations, including strategy, policies and program development. Prior to joining Multiplan, she held senior human resources roles at Private Healthcare Systems, Inc., Oxford Global Resources, Inc., and Randstad North America.

Portrait

Alejandra Carvajal, Chief Legal Officer and General Counsel

See bio

Alejandra V. Carvajal, J.D., joined Momenta as Vice President, Deputy General counsel in June 2017 and has served as the company's Chief Legal Officer, General Counsel & Secretary since October 2018. Ms. Carvajal is responsible for all legal matters and operations at the company.  Prior to joining Momenta, Ms. Carvajal was Vice President and General Counsel of Cerulean Pharma, a public biotechnology company, from September 2014 until June 2017.  Prior to Cerulean, Ms. Carvajal worked at Millennium: The Takeda Oncology Company from 2004 to 2014, where she held a variety of legal positions of increasing seniority. Ms. Carvajal began her legal career in private practice with the law firms of Day, Berry &Howard and Hill & Barlow. Ms. Carvajal received a B.A. cum laude from Harvard University and a J.D. cum laude from Georgetown University Law Center.

Portrait

Ian D. Fier, Chief Operating Officer

See bio

Mr. Fier joined Momenta in October of 2002. Mr. Fier is responsible for overseeing our bioprocess development, analytical development and quality functions, manufacturing technical operations, and program and portfolio management. He was previously Vice President of Clinical Affairs at BioTransplant Inc. where he led a clinical development group responsible for the development and commercialization of both antibody-based therapeutics and medical devices. Prior to that, he held positions in product development and project management at Hoechst-Roussel (now Sanofi Aventis), Astra USA and The Medicines Company and was involved with the development and launch of several successful products. Mr. Fier received his BS from Tufts University and a MBA with a concentration in Heath Care Management from Boston University.

Portrait

Anthony Manning,, Ph.D., Chief Scientific Officer

See bio

Dr. Manning joined Momenta in January 2013. He is responsible for research and driving the discovery of novel products. Since joining Momenta, his teams have advanced three novel autoimmune drugs nipocalimab (M281), M230, and M254 into development and implemented a research engine to discover novel, first-in-class therapeutics for rare immune-related diseases. Prior to Momenta, Dr. Manning was Senior Vice President of Research and Preclinical Development at Aileron Therapeutics. Before that, he was Vice President and Head of Immunology Research for Biogen Idec, Inc. Before that, he was Vice President and Global Head of Inflammation, Autoimmunity and Transplantation Research at Roche Pharmaceuticals.